NCT06075368View on ClinicalTrials.gov

Efficacy and Safety of GENOSS® SES in Patients with Acute Coronary Syndrome (GENOSS ACS)

Active, not recruitingOBSERVATIONAL
Enrollment

757

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Acute Coronary SyndromePercutaneous Coronary Intervention
Interventions
DEVICE

GENOSS Sirolimus Eluting Coronary Stent System

The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Genoss Co., Ltd.

INDUSTRY